Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model

Harris, Lynnea D, Regan, Michael C, Myers, Scott J, Nocilla, Kelsey A, Akins, Nicholas S, Tahirovic, Yesim A, Wilson, Lawrence J, Dingledine, Ray, Furukawa, Hiro, Traynelis, Stephen F, Liotta, Dennis C (February 2023) Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model. ACS Chemical Neuroscience. ISSN 1948-7193

PDF 2023-Furukawa-Novel-GluN2B-Selective-NMDA-Receptor-Negative-Allosteric-Modulator-Possesses-Intrinsic-Analgesic-Properties-and-Enhances-Analgesia-of-Morphine-in-a-Rodent-Tail-Flick-Pain-Model.pdf Available under License Creative Commons Attribution. Download (5MB)

Abstract

Many cases of accidental death associated with drug overdose are due to chronic opioid use, tolerance, and addiction. Analgesic tolerance is characterized by a decreased response to the analgesic effects of opioids, requiring increasingly higher doses to maintain the desired level of pain relief. Overactivation of GluN2B-containing N-methyl-d-Aspartate receptors is thought to play a key role in mechanisms underlying cellular adaptation that takes place in the development of analgesic tolerance. Herein, we describe a novel GluN2B-selective negative allosteric modulator, EU93-108, that shows high potency and brain penetrance. We describe the structural basis for binding at atomic resolution. This compound possesses intrinsic analgesic properties in the rodent tail immersion test. EU93-108 has an acute and significant anodyne effect, whereby morphine when combined with EU93-108 produces a higher tail flick latency compared to that of morphine alone. These data suggest that engagement of GluN2B as a target has utility in the treatment of pain, and EU93-108 could serve as an appropriate tool compound to interrogate this hypothesis. Future structure-activity relationship work around this scaffold could give rise to compounds that can be co-administered with opioids to diminish the onset of tolerance due to chronic opioid use, thereby modifying their utility.

Item Type:	Paper
Subjects:	bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > NMDA receptor organism description > animal bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > glutamate receptor organism description > animal > mammal organism description > animal > mammal > rodent
CSHL Authors:	Regan, Michael Furukawa, Hiro
Communities:	CSHL labs > Furukawa lab
SWORD Depositor:	CSHL Elements
Depositing User:	CSHL Elements
Date:	13 February 2023
Date Deposited:	21 Feb 2023 17:24
Last Modified:	08 Jan 2024 21:21
PMCID:	PMC9983021
URI:	https://repository.cshl.edu/id/eprint/40844

Actions (login required)

Administrator's edit/view item